Prenetics Raises 2026 Outlook on 15% Revenue Growth
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
preneticsgenomics
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Hong Kong-listed genomics and diagnostics firm Prenetics Global Limited (NASDAQ: PRE) announced a revised, higher full-year financial outlook on 10 June 2026, following the release of stronger-than-anticipated first-quarter results. The company reported quarterly revenue growth of 15% year-over-year, a key driver behind the decision to raise its 2026 guidance. The announcement marks a strategic inflection point for a firm that has navigated significant post-pandemic volatility in the testing market. The new outlook specifically targets core operational profitability, moving beyond the one-time gains that characterized earlier financial periods.
The upgrade arrives as global equity markets demonstrate selective appetite for healthcare innovation stocks with clear paths to profitability. The NASDAQ Biotechnology Index (NBI) is up 4.2% year-to-date, underperforming the broader NASDAQ Composite's 8.1% gain, indicating investor scrutiny of biotech business models. Prenetics' prior financial performance was heavily influenced by COVID-19 testing revenue, which peaked in 2022 and subsequently normalized, creating a volatile earnings profile that pressured its share price.
The critical catalyst for the revised outlook is the sustained commercial traction of its non-COVID precision oncology and genetic testing services. These higher-margin, recurring revenue streams are now scaling to offset the decline in pandemic-related income. This shift demonstrates the execution of a multi-year strategic pivot away from cyclical testing and toward a stable portfolio of clinical diagnostics and preventive health tools. The timing is crucial for regaining institutional investor confidence after a steep share price decline from its 2022 highs.
Prenetics' first-quarter revenue reached $28.5 million, a 15% increase from the $24.8 million reported in Q1 2025. The company's gross margin expanded to 52%, up from 48% in the prior-year quarter, reflecting the favorable product mix shift toward higher-value services. Management raised its full-year 2026 revenue guidance to a range of $115-$125 million, up from the previous forecast of $105-$115 million issued in March.
| Metric | Previous 2026 Outlook | Revised 2026 Outlook | Change |
|---|---|---|---|
| Revenue | $105M - $115M | $115M - $125M | +9.5% at midpoint |
| Adjusted EBITDA | Breakeven | $5M - $10M Profit | Positive inflection |
The company ended the quarter with $85 million in cash and equivalents, providing a runway for continued investment. Prenetics' market capitalization stands at approximately $120 million, a fraction of its $300 million valuation at its 2022 debut via SPAC merger. The stock trades at a forward price-to-sales ratio of 1.0x based on the new guidance midpoint, a discount to the peer group average of 2.5x for small-cap diagnostic firms.
The guidance lift is a positive signal for the underperforming small-cap genomics sector, potentially improving sentiment for peers like Burning Rock Biotech (BNR) and Genetron Holdings (GTH). These firms are similarly transitioning from research services to clinical diagnostics, and Prenetics' commercial validation could ease investor concerns about total addressable market size. Suppliers of sequencing equipment and consumables, such as Illumina (ILMN) and Pacific Biosciences (PACB), may see incremental demand upside from increased testing volumes.
A key risk to the thesis is execution on the raised targets, as the new guidance implies an acceleration of growth in the coming quarters without major new product launches. The company must demonstrate it can achieve this growth while controlling sales and marketing expenses, which have historically been elevated. Positioning data shows a recent increase in short interest, suggesting some skepticism remains, but options flow points to growing institutional call buying for the January 2027 expiry, targeting a share price above $3.50.
The next immediate catalyst is the Q2 2026 earnings report, expected in late August. Investors will scrutinize revenue progression toward the $120 million annualized run rate and any updates on the profitability timeline. A key level to watch is the $2.80 share price, which represents the 200-day moving average; a sustained break above could signal a longer-term trend reversal.
The company's planned launch of a new multi-cancer early detection blood test in Q4 2026 represents a major commercial and clinical milestone. Successful early adoption data could serve as a further positive catalyst. any partnership announcements with larger pharmaceutical or healthcare systems to deploy its diagnostic platforms would validate the scalability of its technology and provide further revenue visibility into 2027.
Prenetics has pivoted its business toward precision oncology and genetic health. Its core offerings now include Circle Snapshot, a whole genome sequencing service for health insights, and ACT Genomics, a suite of tissue and liquid biopsy tests that guide cancer therapy decisions. These products target the growing market for personalized, data-driven preventive care and treatment optimization, moving the company into competition with established diagnostic labs.
The new 2026 revenue target of up to $125 million remains below the company's peak revenue of over $200 million in 2022, which was driven by COVID-19 testing. The critical difference is the quality and sustainability of earnings. The current forecast is built on higher-margin, recurring clinical diagnostics, whereas the 2022 revenue was largely low-margin and non-recurring. The shift to positive Adjusted EBITDA is a milestone not achieved during the pandemic boom.
With $85 million in cash and no debt, Prenetics has a substantial runway. At its current operating burn rate, the company has over three years of liquidity, which management states is sufficient to fund operations through to profitability under the new plan. This strong balance sheet reduces near-term dilution risk and provides flexibility to invest in sales expansion and R&D for its pipeline, including the multi-cancer early detection test.
Prenetics' raised outlook validates its business model shift toward profitable precision medicine, offering a necessary catalyst for a deeply undervalued stock.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.